Modality
Small Molecule
MOA
AHRant
Target
MET
Pathway
Tau
SMAPsoriasis
Development Pipeline
Preclinical
~Jan 2013
→ ~Apr 2014
Phase 1
~Jul 2014
→ ~Oct 2015
Phase 2
~Jan 2016
→ ~Apr 2017
Phase 3
Jul 2017
→ May 2030
Phase 3Current
NCT07637060
1,665 pts·SMA
2025-01→2029-08·Completed
NCT05337345
1,559 pts·SMA
2024-05→2025-03·Active
NCT08604280
1,563 pts·Psoriasis
2021-11→2030-05·Completed
+1 more trial
5,162 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (4)
2025-03-091.1y agoPh3 Readout· SMA
2029-01-172.8y awayPh3 Readout· SMA
2029-08-033.3y awayPh3 Readout· SMA
2030-05-044.1y awayPh3 Readout· Psoriasis
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P3
Termina…
P3
Complet…
P3
Active
P3
Complet…
Catalysts
Ph3 Readout
2025-03-09 · 1.1y ago
SMA
Ph3 Readout
2029-01-17 · 2.8y away
SMA
Ph3 Readout
2029-08-03 · 3.3y away
SMA
Ph3 Readout
2030-05-04 · 4.1y away
Psoriasis
ActiveCompletedTerminated|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07637060 | Phase 3 | SMA | Completed | 1665 | DAS28 |
| NCT05337345 | Phase 3 | SMA | Active | 1559 | UPDRS |
| NCT08604280 | Phase 3 | Psoriasis | Completed | 1563 | FEV1 |
| NCT06730313 | Phase 3 | SMA | Terminated | 375 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | MET | |
| BII-5449 | Biogen | Phase 3 | FXIa | |
| Elratapinarof | Halozyme | Phase 2 | C5 | |
| Nidaratamab | Exelixis | Phase 3 | FLT3 | |
| RVM-274 | Revolution Medicines | Phase 3 | MET | |
| NTL-2576 | Intellia | NDA/BLA | SGLT2 | |
| Talazasiran | Kymera | NDA/BLA | MET | |
| RAP-2478 | Rapport Ther | Phase 3 | MET |